ArticleCardiology journal2026
The evolution of concomitant mitral regurgitation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: a prospective multi-center China-DVD2 cohort study.
Article in Cardiology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere aortic stenosis (AS) often coexists with mitral regurgitation (MR). This study evaluated the significant evolution of MR in patients undergoing transcatheter aortic valve replacement (TAVR) for AS.
methodsThis multi-center China Degenerative Valve Disease II Cohort (China-DVD2) Study enrolled patients undergoing TAVR for AS from January 2020 to October 2023. MR severity was assessed at baseline and 12 months post-TAVR. Composite endpoints included all-cause death, heart failure rehospitalization, myocardial infarction, and angina.
resultsAmong 424 enrolled patients, 130 (31%) had significant MR at baseline. At 12 months, MR improved in 56 (70%) of 80 patients with follow-up, and greater improvement in left ventricular ejection fraction (LVEF) was associated with MR improvement [odds ratios (OR): 0.97, 95% confidence interval (CI): 0.95-1.00, p = 0.04)]. Patients with MR improvement showed significant New York Heart Association (NYHA) functional class improvement at 12-month follow-up. No survival benefit disparity was observed between patients with and without significant baseline MR, but a trend toward lower composite endpoint rate (12.5% vs. 20.8%, log-rank p = 0.49) was observed in patients with MR improvement. Older age [hazard ratios (HR): 1.12, 95% CI: 1.01-1.24, p = 0.04)] and higher systolic pulmonary arterial pressure (SPAP) (HR: 1.05, 95% CI: 1.00-1.09, p = 0.04) were linked to worse outcomes.
conclusionsMost patients with significant MR experienced improvement of NYHA class and MR post TAVR. Baseline significant MR was not linked to worse outcomes, but MR improvement showed a trend toward better prognosis. Older age and higher SPAP predicted worse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.